Owing to a number of attractive traits, the Asian continent is well positioned to become the preferred destination for cost-effective clinical trials. This can be demonstrated by a 7-fold increase in the number of registered clinical trials in Asia over the last decade (Ali et al., 2019). Firstly, Asia is becoming increasingly attractive as a clinical trial destination due to its presence of heterogenous population groups. Asia is the most populated continent in the world, with 4.4 billion people living on the continent alone – more than half of the world’s population (Statista, n.d.). Secondly, Asia has access to larger patient pools providing a comparable environment to carry out clinical trials.
For instance, pharmaceutical companies would be more likely to conduct liver or gastroesophageal cancer treatment trials in Korea or even in China, because these countries provide a large pool of patients for conducting trials for these diseases (Lee et al., 2014). Thirdly, Asia offers lower costs for clinical trials, which are between 30 % and 40 % lower than in Western countries. Lastly, Asia has knowledgeable key opinion leaders (KOLs) and experts across a wide range of therapeutic areas. For example, China alone has 17 academic institutions and hospitals that have made a significant contribution to regenerative medicine research and has over 70 active trials.
At Choice we recognise the benefits UK Trials Imaging expertise can offer to China and East Asia. Our USPs are having innovative global imaging platform technology, and a vast network of leading UK Specialist Consultants with extensive experience in trials and research. An example of how Clinical trials in Asia could benefit is by completing one scan read in the UK. Benefits in this example would include an additional layer of expertise, mitigating bias and demonstrating independence through peer view from the UK, adding monetary value to trial outcomes, and subsequently enhancing your organisational value. Hence, Choice Health are an ideal UK partner to complement your clinical trials in Asia.
If you are attending ChinaBio August 25-27th 2020, we’d be delighted to (virtually) meet up and discuss further.
About The Author
Pauric Greenan is an experienced PACS consultant that has been PACS lead on several high-profile PACS projects in both the UK and Ireland. Pauric is internationally available for PACS consulting. Contact him here for more details.
Did you know that we are able to fulfil a variety of your imaging diagnostic needs?
Choice Health is highly experienced in clinical trial and research imaging, PACS consultancy, telehealth, imaging AI and medical physics.
Would you like a free consultation to see if we’re a match? If so, do not hesitate to reach out via our contact page.
